PL2048948T3 - Płynne kompozycje octanu wapnia - Google Patents

Płynne kompozycje octanu wapnia

Info

Publication number
PL2048948T3
PL2048948T3 PL07836163T PL07836163T PL2048948T3 PL 2048948 T3 PL2048948 T3 PL 2048948T3 PL 07836163 T PL07836163 T PL 07836163T PL 07836163 T PL07836163 T PL 07836163T PL 2048948 T3 PL2048948 T3 PL 2048948T3
Authority
PL
Poland
Prior art keywords
calcium acetate
liquid compositions
individual
sweetener
administering
Prior art date
Application number
PL07836163T
Other languages
English (en)
Inventor
Stephen C Tarallo
Original Assignee
Lyne Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38957385&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2048948(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lyne Laboratories Inc filed Critical Lyne Laboratories Inc
Publication of PL2048948T3 publication Critical patent/PL2048948T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07836163T 2006-07-21 2007-07-20 Płynne kompozycje octanu wapnia PL2048948T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83209306P 2006-07-21 2006-07-21
EP07836163A EP2048948B1 (en) 2006-07-21 2007-07-20 Liquid compositions of calcium acetate
PCT/US2007/016415 WO2008011126A2 (en) 2006-07-21 2007-07-20 Liquid compositions of calcium acetate

Publications (1)

Publication Number Publication Date
PL2048948T3 true PL2048948T3 (pl) 2012-07-31

Family

ID=38957385

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07836163T PL2048948T3 (pl) 2006-07-21 2007-07-20 Płynne kompozycje octanu wapnia
PL11192965T PL2484352T3 (pl) 2006-07-21 2007-07-20 Płynne kompozycje octanu wapnia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11192965T PL2484352T3 (pl) 2006-07-21 2007-07-20 Płynne kompozycje octanu wapnia

Country Status (18)

Country Link
US (3) US8591938B2 (pl)
EP (2) EP2048948B1 (pl)
JP (1) JP5335674B2 (pl)
KR (1) KR101553719B1 (pl)
CN (2) CN104095838A (pl)
AT (1) ATE547099T1 (pl)
AU (1) AU2007275606B9 (pl)
BR (1) BRPI0714882A2 (pl)
CA (1) CA2658465C (pl)
ES (1) ES2382993T3 (pl)
HK (1) HK1202815A1 (pl)
IL (1) IL196584A0 (pl)
MX (1) MX2009000722A (pl)
NZ (1) NZ574331A (pl)
PL (2) PL2048948T3 (pl)
RU (1) RU2463060C2 (pl)
WO (1) WO2008011126A2 (pl)
ZA (1) ZA200900472B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771470B1 (en) * 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
KR20190006086A (ko) * 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
PL2048948T3 (pl) 2006-07-21 2012-07-31 Lyne Laboratories Inc Płynne kompozycje octanu wapnia
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
DK2124999T3 (da) * 2006-12-18 2013-01-14 Acceleron Pharma Inc Activin-actrii antagonister og anvendelser til behandling af anæmi
EP2111229B1 (en) * 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) * 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) * 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP3243524A1 (en) * 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
JP5773868B2 (ja) * 2008-06-26 2015-09-02 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
AU2009262970A1 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
SMT202300222T1 (it) * 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8138142B2 (en) * 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
BRPI1010587A2 (pt) * 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
EP3818988A1 (en) * 2009-11-03 2021-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
JP6267425B2 (ja) * 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
JP5766021B2 (ja) * 2010-05-14 2015-08-19 興和株式会社 安定な水性液剤
EP2441436A1 (de) 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
BE1019709A3 (fr) * 2010-12-22 2012-10-02 Calxx Laboratoires S A Produit alimentaire organo-mineral et procede de preparation.
US9149529B2 (en) * 2012-10-24 2015-10-06 Orthovita, Inc. Stable compositions containing thrombin and methods for preparation and use thereof
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
CN104688681B (zh) * 2015-03-17 2018-01-02 常州康普药业有限公司 利巴韦林口服液及其制备方法
JP6718212B2 (ja) * 2015-08-17 2020-07-08 三菱商事ライフサイエンス株式会社 酢酸カルシウムのえぐ味抑制方法
GB2551971B (en) * 2016-06-29 2020-09-16 Syri Ltd Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof
WO2020150460A1 (en) * 2019-01-18 2020-07-23 Milne Iii Donald A Micronized aspirin formulation
WO2020210608A1 (en) 2019-04-12 2020-10-15 Biolink Life Sciences, Inc. Liquid concentrates of calcium and magnesium
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
CN120078716A (zh) * 2025-02-28 2025-06-03 北京远方通达医药技术有限公司 一种醋酸钙口服溶液的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093710A (en) * 1976-07-07 1978-06-06 Sandoz, Inc. Rapid dissolving effervescent granules
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
JPS6136222A (ja) 1984-07-26 1986-02-20 Chugai Pharmaceut Co Ltd 高リン酸血症治療剤
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
US4870105B1 (en) * 1987-04-07 1998-03-10 Braintree Lab Phosphorus binder
CN1067250A (zh) 1991-05-28 1992-12-23 北京师范大学 桐酸系间苯二酚甲醛树脂的合成方法
DE19528524C2 (de) 1995-08-03 1999-11-11 Hans Dietl Calciumhaltiges Mittel zur intestinalen Phosphatbindung und Verfahren zu seiner Herstellung
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US5833954A (en) * 1996-08-20 1998-11-10 American Dental Association Health Foundation Anti-carious chewing gums, candies, gels, toothpastes and dentifrices
CN1162489A (zh) 1997-02-25 1997-10-22 青岛盖宝特保健品有限公司 酪磷肽钙营养液
CN1067250C (zh) 1997-08-21 2001-06-20 中国人民解放军总装备部后勤部军事医学研究所 中性补钙制剂
US5976507A (en) * 1998-06-04 1999-11-02 Colgate Palmolive Company Dentrifice composition containing encapsulated reactive ingredients
US5858333A (en) * 1998-08-07 1999-01-12 Enamelon, Inc. Two-part oral products and methods of using same to remineralize teeth
DE19917705C1 (de) 1999-04-20 2000-12-28 Vitasyn Gmbh Mittel zur Therapie von Hyperphosphatämie
CN1242963A (zh) 1999-07-26 2000-02-02 李久成 补钙可乐及其制备方法
CN1252278A (zh) 1999-09-16 2000-05-10 冯荣根 锌钙海狸营养品
JP2001204440A (ja) * 2000-01-25 2001-07-31 Mitsukan Group Honsha:Kk カルシウム飲料
YU8803A (sh) * 2000-08-07 2006-01-16 Ranbaxy Signature L.L.C. Tečni oblik metformina
CN1159993C (zh) 2000-10-26 2004-08-04 李久成 一种强化多元素离子饮料及其制备方法
US6576665B2 (en) * 2001-04-03 2003-06-10 Braintree Laboratories, Inc. Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption
US20030026872A1 (en) * 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
WO2002096393A1 (en) 2001-05-29 2002-12-05 Potchefstroom University For Christian Higher Education Anorexic composition comprising calcium acetate
JP2002363105A (ja) * 2001-05-31 2002-12-18 Taiho Yakuhin Kogyo Kk 不快な味のマスキング方法及び内服用液剤
ITMI20011284A1 (it) 2001-06-19 2002-12-19 Salvatore Bilardello Composizione farmaceutica per il trattamento dell'iperfosfatemia
US6887897B2 (en) * 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
GB2395124A (en) 2002-11-16 2004-05-19 Fluid Technologies Plc Palatable microcapsules
AU2003295589A1 (en) * 2002-11-22 2004-06-18 Noville, Inc. Oral compositions which mask the salty taste of salts
JP4996458B2 (ja) 2004-06-01 2012-08-08 ニコメド ファーマ エイエス 活性物質としてカルシウム含有化合物を含み、咀嚼し、舐め、飲み込むことのできる錠剤
GB2416981A (en) 2004-08-13 2006-02-15 Nutraceuticals Ltd Premixes, flour enriched with same, mineral supplemented foodstuffs and methods of manufacture therefore.
US7862836B2 (en) * 2005-04-12 2011-01-04 Biolink Life Sciences, Inc. Phosphorus binder for treatment of kidney disease
PL2048948T3 (pl) 2006-07-21 2012-07-31 Lyne Laboratories Inc Płynne kompozycje octanu wapnia

Also Published As

Publication number Publication date
CN101522021B (zh) 2014-07-30
EP2048948A4 (en) 2009-11-11
HK1202815A1 (en) 2015-10-09
NZ574331A (en) 2011-01-28
ATE547099T1 (de) 2012-03-15
US20140255515A1 (en) 2014-09-11
US9089528B2 (en) 2015-07-28
EP2048948A2 (en) 2009-04-22
EP2048948B1 (en) 2012-02-29
WO2008011126A3 (en) 2008-09-18
MX2009000722A (es) 2009-06-11
CA2658465A1 (en) 2008-01-24
PL2484352T3 (pl) 2014-12-31
JP5335674B2 (ja) 2013-11-06
HK1129814A1 (en) 2009-12-11
AU2007275606B9 (en) 2013-09-26
IL196584A0 (en) 2009-11-18
CA2658465C (en) 2016-06-14
RU2009104774A (ru) 2010-08-20
US20110251282A1 (en) 2011-10-13
US20080021104A1 (en) 2008-01-24
BRPI0714882A2 (pt) 2013-05-21
ZA200900472B (en) 2009-11-25
US8591938B2 (en) 2013-11-26
AU2007275606B2 (en) 2013-06-06
EP2484352B1 (en) 2014-07-09
CN104095838A (zh) 2014-10-15
KR101553719B1 (ko) 2015-09-16
RU2463060C2 (ru) 2012-10-10
JP2009544615A (ja) 2009-12-17
KR20090040340A (ko) 2009-04-23
ES2382993T3 (es) 2012-06-15
CN101522021A (zh) 2009-09-02
EP2484352A1 (en) 2012-08-08
WO2008011126A2 (en) 2008-01-24
US8592480B2 (en) 2013-11-26
AU2007275606A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
ZA200900472B (en) Liquid compositions of calcium acetate
WO2007117778A8 (en) Quinolones useful as inducible nitric oxide synthase inhibitors
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008013838A3 (en) Pyridizinone derivatives
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
TW200612892A (en) Novel compounds
WO2008144346A3 (en) Crystal structures of sglt2 inhibitors and processes for their preparation
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2008011364A3 (en) Quercetin-containing compositions
WO2007135241A3 (en) Composition and method for binding acetaldehyde in stomach
WO2008017346A3 (de) Ascorbinsäurederivate, verwendung zur funktionalisierung von matrices
WO2007036363A8 (de) Zusammensetzungen, welche buttersäureester von kohlenhydraten und kohlenhydratpolyolen enthalten
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2007052023A3 (en) Novel compounds
TW200621690A (en) Novel compounds
WO2007144778A3 (en) Herbal compositions for the prevention or treatment of a urinary tract infection
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
WO2009100275A3 (en) Compositions and devices
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
WO2010121213A3 (en) Antibacterial compositions
WO2008033935A3 (en) Vinorelbine derivatives
WO2007104933A8 (en) Chemical compounds
MY147271A (en) Accelerating agent of calcium absorption
WO2007138462A3 (en) Aqueous oral formulations of risperidone
WO2007115287A3 (en) Combination of organic compounds